News Releases

Keyword search

Date Title  
Toggle Summary AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain
REDWOOD CITY, Calif. , Nov. 16, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a manuscript
Toggle Summary AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results
- $67.9 million of cash and cash equivalents at September 30, 2017 - Type A FDA meeting requested and Briefing Book submitted to FDA regarding DSUVIA complete response letter (CRL) REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
Toggle Summary AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department
REDWOOD CITY, Calif. , Nov. 9, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, reported the publication of a manuscript
Toggle Summary AcelRx Pharmaceuticals to Hold Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 9th
REDWOOD CITY, Calif. , Oct. 30, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 9th .
Toggle Summary AcelRx's DSUVIA™ Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY® 2017
DSUVIA clinical trial results was one of the top eight abstracts featured as an oral presentation at an opioid pharmacotherapy symposium at ANESTHESIOLOGY® 2017 REDWOOD CITY, Calif. , Oct. 20, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical,
Toggle Summary AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA
REDWOOD CITY, Calif. , Oct. 12, 2017 /PRNewswire/--  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) (AcelRx), a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) regarding its New Drug Application
Toggle Summary AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September
REDWOOD CITY, Calif. , Sept. 6, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Vincent
Toggle Summary AcelRx Pharmaceuticals Reports Successful Outcome of ZALVISO Phase 3 IAP312 Study on Device Functionality
- Study Objective Achieved with 2.2% of Patients Experiencing a Device Error - - AcelRx Remains on Track to Resubmit NDA by End of 2017 - REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today provided a business update
Toggle Summary AcelRx Pharmaceuticals to Hold a Conference Call and Webcast on Tuesday, August 1st to Discuss ZALVISO Phase 3 Top-line Data and Quarterly Financial Results
REDWOOD CITY, Calif., July 31, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that it will
Toggle Summary AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
REDWOOD CITY, Calif., July 19, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced the appointment of Raffi
Toggle Summary AcelRx Pharmaceuticals' ZALVISO Recognized for Innovative Design with Prestigious Red Dot Award
REDWOOD CITY, Calif., June 1, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that ZALVISO
Toggle Summary AcelRx Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference
REDWOOD CITY, Calif., May 31, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Vincent J.
Toggle Summary AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
- NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) and MAA for ARX-04 under review at respective agencies - REDWOOD CITY, Calif., May 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development
Toggle Summary AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May 8th, 2017
REDWOOD CITY, Calif. , April 26, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that it will
Toggle Summary AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual Patient-Controlled Analgesia Systems
REDWOOD CITY, Calif. , April 13, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that Grunenthal, the
Toggle Summary AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual Regional Anesthesiology and Acute Pain Medicine Meeting
REDWOOD CITY, Calif. , April 6, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that efficacy and integrated
Toggle Summary European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain
CHMP Opinion Expected First Half 2018 REDWOOD CITY, Calif. , March 28, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain,
Toggle Summary AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April
REDWOOD CITY, Calif. , March 17, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Senior
Toggle Summary AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA™ at Upcoming Congresses
REDWOOD CITY, Calif. , March 16, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, will present data from the DSUVIA™
Toggle Summary AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
- DSUVIA NDA Accepted and PDUFA Date Set for October 12, 2017 - REDWOOD CITY, Calif. , March 2, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment
Toggle Summary AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in March
REDWOOD CITY, Calif. , March 1, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy
Toggle Summary AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017
REDWOOD CITY, Calif. , Feb. 27, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced today the U.S.
Toggle Summary AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on Thursday, March 2nd, 2017
REDWOOD CITY, Calif. , Feb. 23, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that it will release fourth
Toggle Summary AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
- Howie Rosen to Continue on Board of Directors - REDWOOD CITY, Calif. , Feb. 16, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe
Toggle Summary AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif. , Feb. 13, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced an upcoming podium presentation
Toggle Summary AcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February
REDWOOD CITY, Calif. , Feb. 7, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that Timothy E.
Toggle Summary AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
· Expected FDA Acceptance of the NDA · Planned Submission of MAA in the EU · Potential Approval and Commercialization in the U.S. REDWOOD CITY, Calif. , Jan. 8, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and
Toggle Summary AcelRx Pharmaceuticals Announces DSUVIA™ as Brand Name for ARX-04 in the United States
REDWOOD CITY, Calif. , Jan. 8, 2017 /PRNewswire/ --  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that the U.S.
Print PageRSS Feeds